Bimekizumab shows lasting efficacy at EULAR 2025

Three-year data highlights inflammation control in psoriatic arthritis

UCB has announced new three-year data from phase 3 trials and their open-label extensions investigating BIMZELX (bimekizumab) in psoriatic arthritis and axial spondyloarthritis.

The results, presented at EULAR 2025, show sustained inflammation control and significant long-term improvements in symptom relief and physical function.

In psoriatic arthritis, 53.2% of biologic-naïve patients and 55.2% of those with prior inadequate response to tumour necrosis factor inhibitors maintained ACR50 at three years. Swollen joints were eliminated in nearly 60% of patients, while approximately half achieved minimal disease activity, indicating strong inflammation control.

Professor Laure Gossec from Sorbonne University Hospital said: “These bimekizumab data are notable for their consistency across treatment-naïve and experienced patients.”

In axial spondyloarthritis, long-term efficacy was maintained across both non-radiographic and radiographic disease subtypes. ASAS40 was achieved by 60.4% of patients with non-radiographic axial spondyloarthritis and 60.1% with radiographic axial spondyloarthritis at three years. Low disease activity, measured by ASDAS, was maintained by 61.8% and 59.9% of patients, respectively.

Professor Xenofon Baraliakos from Ruhr University Bochum said: “These endpoints are key indicators of durable inflammation control in axial spondyloarthritis.”

Bimekizumab is the first and only approved treatment designed to selectively inhibit interleukin 17A and interleukin 17F. The data presented reinforce its potential as a long-term treatment option for chronic inflammatory diseases.

UCB remains committed to advancing innovation in rheumatology, with additional presentations at EULAR 2025 and ongoing phase 3 trials in psoriatic arthritis and axial spondyloarthritis.